Latest news and insights on the pharmaceutical industry | Indian Pharma Post

Results For "MeziKd"

2 News Found

Bristol Myers Squibb’s mezigdomide cuts myeloma progression risk by 52%
R&D | May 31, 2026

Bristol Myers Squibb’s mezigdomide cuts myeloma progression risk by 52%

MeziKd delivered stronger response rates across multiple patient groups, including those receiving second- and third-line treatment and patients with higher-risk disease


Bristol Myers Squibb reports positive phase 3 results for oral multiple myeloma therapy
Clinical Trials | March 10, 2026

Bristol Myers Squibb reports positive phase 3 results for oral multiple myeloma therapy

The interim results of the Phase 3 SUCCESSOR-2 study's safety profile aligned with expectations for both mezigdomide and the combination regimen